health
diciembre 28, 2025
Las autoridades estadounidenses aprueban uso de píldora para adelgazar de Novo Nordisk
Las autoridades sanitarias de FDA aprobaron el uso en píldora del medicamento para adelgazar Wegovy, desarrollado por Novo Nordisk, convirtiéndose en la primera terapia oral basada en GLP-1 autorizada en Estados Unidos para el control del peso
TL;DR
- The FDA has approved Wegovy as a pill for weight loss.
- This is the first oral GLP-1 therapy authorized in the United States for weight control.
- The Oasis 4 trial showed participants lost 16.6% of their body weight in 64 weeks.
- The weight loss achieved with the pill is similar to the injectable Wegovy.
- Novo Nordisk plans to launch the new medication in early January.
- Novo Nordisk's stock rose nearly 8% following the announcement.